650 East Kendall Street
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
Stock Symbol: TAK
Science is the foundation for everything we do at Takeda. We connect to our 240- year history and our strong values through our pursuit of life-transforming science where we embrace a culture of collaboration, pursue modalities based on validated targets, evaluate real-world impact and generate data that may enable accelerated development and regulatory pathways.
1450 articles about Takeda
Takeda Pharmaceutical Co. Ltd. Pain Drug Pulled, Called Useless
Takeda Pharmaceutical Co. Ltd. Enters into Partnership with Quintiles, Inc. and Covance Inc.
Takeda Pharmaceutical Co. Ltd. Enters Into Global Strategic Partnerships With Covance Inc. and Quintiles, Inc.
Takeda Pharmaceutical Co. Ltd. Begins Phase III Trial of Diabetes Drug in China
Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd. Announce New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan
Sanofi-Aventis K.K., Takeda Pharmaceutical Co. Ltd. Drugs on FDA Early Safety Probe List
Takeda Pharmaceutical Co. Ltd. and Zinfandel Pharmaceuticals Inc. Sign Licensing Agreement for Alzheimer's Disease Biomarker in Combination with Pioglitazone; Zinfandel to Receive $9M Upfront, Payments of up to $78M
Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceutical Co. Ltd. Initiate Third Phase 3 Clinical Trial of Lubiprostone in Opioid-Induced Bowel Dysfunction
Teva Pharmaceutical Industries Limited, Takeda Pharmaceutical Co. Ltd. In Deal To Settle Actos Patent Suit
Takeda Pharmaceuticals North America, Inc. Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS(R) (pioglitazone HCI), ACTOplus met(R) (pioglitazone HCl and metformin HCl) and duetact(R) (pioglitazone HCl and glimepiride)
Seattle Genetics, Inc. and Takeda Pharmaceutical Co. Ltd. Leads Roche in Race to Develop Combo Cancer Therapy
Baxter International, Inc. and Takeda Pharmaceutical Co. Ltd. Complete Agreement for Vero Cell-Based Influenza Vaccines in Japan
Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. Confirm U.S. Registration Strategy for Investigational Drug, Hematide(TM)/Peginesatide, Following Meeting with FDA
Johnson & Johnson, Takeda Pharmaceutical Co. Ltd. Recall Batches of Cancer Drug Velcade
Genzyme Corporation in Talks to Sell Itself to Takeda Pharmaceutical Co. Ltd. for $18.5 Billion
Millennium: The Takeda Oncology Company and Takeda Pharmaceutical Co. Ltd. Announce Advancement of Prostate Cancer Program
Takeda Pharmaceutical Co. Ltd. Obtains 100% Control of China JV
Takeda Pharmaceutical Co. Ltd. and Envoy Therapeutics Form Schizophrenia Research Alliance; Takeda Will Make $3 Million Plus $2.25 Million Each Year
Takeda Pharmaceutical Co. Ltd. Takes Long-Awaited First Step Into India
Takeda Pharmaceutical Co. Ltd. Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.